PRF1 and neoplasm: These modified T cells can directly bind to specific antigens on tumor cell surfaces and become activated, killing tumor cells by releasing perforin, granzyme B, and other cytokines, and recruiting endogenous immune cells for further tumor cell destruction, thereby achieving therapeutic goals (13, 14).